Glucose and Rapamycin for Anti-Aging
It’s pretty clear that aging slowdown is directly related to the reduction of glucose in our blood and that Type-II diabetics drugs, almost all, bring in mammal experimentation a lifespan increase (Metformin, GLP-1 inhibitors such as Semaglutide/Liraglutide and Acarbose)
It’s pretty clear that senolytics effects of AMPK-metabolism, is what drive cleanup of senescent cells.
It has precisely identified the relationship between AMPK and Glucose levels :
“There are many biology observation of relationship between AMPK and Glucose levels, in bi-directional influence, but not a specific anti-aging protocol outside the fact that all diabetes type-II treatments increase lifespan. On the AMPK-Glucose relationship you can see AMP-activated protein kinase signaling in metabolic regulation”
Low level of glucose in blood givens the body understanding of being in a starvation mood, leading to AMPK release and increase of autophagic process.
Furthermore the leading drugs for longevity increase, Rapamycin, take care of inhibiting mTORC1, always associated with lifespan increase:
Low level of glucose, lead to inhibition of mTORC1 :
“when glucose levels are low, mTORC1 is inhibited, in turn leading to the repression of numerous anabolic processes, sparing ATP and antioxidant”
Who takes Rapamcyin as a drug for the purpose of lifespan increase, experience an increase in insuline resistance, basically a “Rapamycin diabets” that can be really damaging. Sirolimus lead to Pancreas’s B-cells dysfunction and death, leading to diabets.
The good news is that glucagon-like peptide-1 receptor (GLP-1R) receptor antagonist, such as the well knows Semaglutide and Liraglutide T2D and weight-losing drugs, reduce such an effect.
By this assumptions, any Rapamycin mTORC1 inhibition longevity therapy should first starts lowing Glucose with existing longevity-increase T2D drugs (that already inhibits mTORC1) such as GLP-1R antagonist, Metformin and Acarbose and only once the glucose-level has been seriously lowered (my target is “slighly above hypoglicemic-level), then introduce Rapamycin.
Discussion on Rapamycin News forum for updates.
This is a working note from a personal research project, not medical advice. Protocols described here were run on one person and measured; nothing on this site is a recommendation to do the same.